drugset / Trial / NCT05896007
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
NaSingle-groupOpen-labelTreatment
Summary
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing zanubrutinib on the basis of rituximab and methotrexate (MTX) \[or temozolomide (TMZ), if intolerant to MTX\] in treating patients newly diagnosed with primary CNS large B-cell lymphoma and intolerant to HSCT.
Timeline
- Start
- 2023-07-13
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |
| Background | Methotrexate | Small molecule | 3.5 g | Other |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Other |
| Background | Temozolomide | Small molecule | 150 mg/m2 | Other |